Sage Details 40% Job Cuts While Zurzuvae’s Future In MDD Remains Unclear
Reorganization Puts Earlier-Stage Programs On Hold
Zurzuvae will launch this year for postpartum depression, but US FDA rejection of the drug in major depressive disorder spurred Sage to cut R&D programs and jobs as it and partner Biogen evaluate next steps in MDD.
You may also be interested in...
CEO Barry Greene and team spoke with Scrip about Sage and Biogen’s focus on short-term, episodic dosing, and said doctors and payers – pending zuranolone’s approval – are responding to the sales pitch.
Data from the Phase III CORAL study of zuranolone showed the drug missing efficacy at day 15, which may dampen its appeal in the real-world setting.
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.